CoChat
Sign Up
Cited by 525Heart Failure Treatment and ManagementAcute Myocardial Infarction ResearchCardiac Fibrosis and Remodeling

The DOI matches its Crossref record.

Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group

Open access
Goldstein, R E, Boccuzzi, S J, Cruess, D, Nattel, S·1991·Circulation
DOI 10.1161/01.cir.83.1.52
Open this paper in CoChat — free accountOpen PDF

Abstract

The Multicenter Diltiazem Postinfarction Trial (MDPIT) reported no consistent diltiazem effect on new or worsened congestive heart failure (CHF) during 12-52 months' follow-up after acute myocardial infarction. This was puzzling in light of the observation that patients with findings suggesting left ventricular dysfunction (LVD) at baseline on diltiazem had more cardiac events (cardiac mortality or recurrent nonfatal infarction) than such patients on placebo. We hypothesized that diltiazem increased the frequency of late CHF as well as of cardiac events, but only in patients predisposed by LVD. Using the same characterizing variables as the primary MDPIT analysis, we found that patients with pulmonary congestion, anterolateral Q wave infarction, or reduced ejection fraction (EF) at baseline were more likely to have CHF during follow-up than those without these markers of LVD. CHF was particularly frequent in the patients with LVD who were randomized to diltiazem. Among those with a baseline EF of less than 0.40, late CHF appeared in 12% (39/326) receiving placebo and 21% (61/297) receiving diltiazem (p = 0.004). Life table analysis in patients with an EF of less than 0.40 confirmed more frequent late CHF in those taking diltiazem (p = 0.0017). In addition, the diltiazem-associated rise in the frequency of late CHF was progressively greater with increasingly severe decrements in baseline EF. This diltiazem effect was absent in patients with pulmonary congestion at baseline but an EF of 0.40 or more, suggesting a unique association between diltiazem-related late CHF and systolic LVD.(ABSTRACT TRUNCATED AT 250 WORDS)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.83.1.52

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

The publisher hasn’t deposited this paper’s reference list.

Research works printed but not linked: 14

  1. Hossack KF, Pool PE, Steel P, Crawford MH, DeMaria AN, Cohen LS, Ports TA: Efficacy of diltiazem in angina on effort: A multicenter trial. Am J Cardiol 1982;49:567-572
  2. Strauss WE, McIntyre KM, Parisi AF, Shapiro W: Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: Report of a cooperative clinical trial. Am J Cardiol 1982;49:560-566
  3. Pepine CJ, Feldman RL, Hill JA, Conti CR, Mehta J, Hill C, Scott E: Clinical outcome after treatment of rest angina with calcium blockers: Comparative experience during the initial year of therapy with diltiazem, nifedipine, and verapamil. Am Heart J 1983;106:1341-1347
  4. Boden WE, Bough EW, Reichman MJ, Rich VB, Young PM, Korr KS, Schulman RS: Beneficial effects of high-dose dil- tiazem in patients with persistent effort angina on p-blockers and nitrates: A randomized, double-blind, placebo-controlled cross-over study. Circulation 1985;71:1197-1205
  5. Porter CB, Walsh RA, Badke FR, O'Rourke RA: Differential effects of diltiazem and nitroprusside on left ventricular function in experimental chronic volume overload. Circulation 1983;68:685-692
  6. Murakami T, Hess OM, Krayenbuehl HP: Left ventricular function before and after diltiazem in patients with coronary artery disease. JAm Coll Cardiol 1985;5:723-730
  7. The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392
  8. Greenberg H, Gillespie J, Dwyer EM Jr, the Multicenter Post-Infarction Research Group: A new electrocardiographic classification for post-myocardial infarction clinical trials. Am J Cardiol 1987;59:1057-1063
  9. Kaplan EL, Meier P: Nonparametric estimation from incom- plete observations. JAm Stat Assoc 1958;53:457-481
  10. Marcus FI, Friday K, McCans J, Moon T, Hahn E, Cobb L, Edwards J, Kuller L: Age-related prognosis after acute myo- cardial infarction (the Multicenter Diltiazem Post-Infarction Trial). Am J Cardiol 1990;65:559-566
  11. Chadda K, Goldstein S, Byington R, Curb JD: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510
  12. Packer M, Gottlieb SS, Kessler PD: Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. The basis of a new physiologic approach to control of arrhythmia. Am J Med 1986;80:23-29
  13. Packer M, Meller J, Medina N, Yushak M, Smith H, Holt J, Guererro J, Todd GD, McAllister RG Jr, Gorlin R: Hemody- namic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 1982;65:660-668
  14. Joshi PI, Dalal JJ, Ruttlet MSJ, Sheridan DJ, Henderson AH: Nifedipine and left ventricular function in beta-blocked patients. Br Heart J 1981;45:457-459

Cited by

Sorted by citations

Items 201–300 of 525

Related

See all

Metadata

Authors
Goldstein, R. E., Boccuzzi, S. J., Cruess, D., & Nattel, S.
Affiliations
Uniformed Services University of the Health Sciences (US)
ORCID
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
1991-01
Volume
83
Issue
1
Pages
52-60
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/01.cir.83.1.52
OpenAlex
W2090674352
Cited by
521
References
0
Citations by year
2026: 5 · 2025: 13 · 2024: 14 · 2023: 16 · 2022: 16 · 2021: 7 · 2020: 24 · 2019: 13 · 2018: 15 · 2017: 17 · 2016: 15 · 2015: 17 · 2014: 4 · 2013: 16 · 2012: 11
FWCI
17.90
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Funders
Henry M. Jackson Foundation
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords
diltiazem, congestive heart failure, myocardial infarction, left ventricular dysfunction, ejection fraction, calcium channel blockers, pulmonary congestion, adverse drug reactions
MeSH terms
Diltiazem, Double-Blind Method, Follow-Up Studies, Heart Failure, Humans, Myocardial Infarction, Stroke Volume, Life Tables, Ventricular Function, Left

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review